ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)
SEK 19.16
(-2.15%)
SEK 19.16
(-2.15%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -105.96 Million SEK | 16.96% |
| 2022 | -127.6 Million SEK | -163.67% |
| 2021 | -48.39 Million SEK | -55.14% |
| 2020 | -31.19 Million SEK | -91.45% |
| 2019 | -16.29 Million SEK | 10.74% |
| 2018 | -18.25 Million SEK | -59.65% |
| 2017 | -11.43 Million SEK | -24.81% |
| 2016 | -9.16 Million SEK | 3.66% |
| 2015 | -9.5 Million SEK | -3504.77% |
| 2014 | 279.3 Thousand SEK | -59.44% |
| 2013 | 688.66 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 1.55 Million SEK | -31.79% |
| 2024 Q2 | -22.06 Million SEK | -1516.11% |
| 2023 Q2 | -33.23 Million SEK | -10.89% |
| 2023 Q4 | 2.28 Million SEK | 110.31% |
| 2023 FY | -105.96 Million SEK | 16.96% |
| 2023 Q3 | -22.16 Million SEK | 33.32% |
| 2023 Q1 | -29.97 Million SEK | 43.54% |
| 2022 Q3 | -32.66 Million SEK | -20.05% |
| 2022 FY | -127.6 Million SEK | -163.67% |
| 2022 Q4 | -53.08 Million SEK | -62.49% |
| 2022 Q2 | -27.21 Million SEK | -85.8% |
| 2022 Q1 | -14.64 Million SEK | 9.53% |
| 2021 Q3 | -9.85 Million SEK | 5.28% |
| 2021 Q1 | -11.94 Million SEK | 29.64% |
| 2021 Q2 | -10.4 Million SEK | 12.88% |
| 2021 FY | -48.39 Million SEK | -55.14% |
| 2021 Q4 | -16.18 Million SEK | -64.23% |
| 2020 Q2 | -4.7 Million SEK | 13.61% |
| 2020 Q1 | -5.44 Million SEK | 15.9% |
| 2020 Q3 | -4.07 Million SEK | 13.42% |
| 2020 FY | -31.19 Million SEK | -91.45% |
| 2020 Q4 | -16.97 Million SEK | -316.92% |
| 2019 Q4 | -6.47 Million SEK | -91.79% |
| 2019 Q1 | -4.79 Million SEK | 18.81% |
| 2019 FY | -16.29 Million SEK | 10.74% |
| 2019 Q3 | -3.37 Million SEK | 3.02% |
| 2019 Q2 | -3.48 Million SEK | 27.36% |
| 2018 Q1 | -3.48 Million SEK | 16.93% |
| 2018 FY | -18.25 Million SEK | -59.65% |
| 2018 Q3 | -4.83 Million SEK | -19.9% |
| 2018 Q2 | -4.03 Million SEK | -15.98% |
| 2018 Q4 | -5.9 Million SEK | -21.95% |
| 2017 Q1 | -1.09 Million SEK | 75.41% |
| 2017 Q3 | -3.16 Million SEK | -6.07% |
| 2017 Q4 | -4.18 Million SEK | -32.35% |
| 2017 FY | -11.43 Million SEK | -24.81% |
| 2017 Q2 | -2.98 Million SEK | -172.01% |
| 2016 Q4 | -4.46 Million SEK | -60.81% |
| 2016 Q2 | -1.92 Million SEK | 78.97% |
| 2016 FY | -9.16 Million SEK | 3.66% |
| 2016 Q1 | -9.16 Million SEK | 0.0% |
| 2016 Q3 | -2.77 Million SEK | -43.95% |
| 2015 FY | -9.5 Million SEK | -3504.77% |
| 2014 FY | 279.3 Thousand SEK | -59.44% |
| 2013 FY | 688.66 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alzinova AB (publ) | -16.52 Million SEK | -541.357% |
| Amniotics AB (publ) | -29.07 Million SEK | -264.479% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -623.805% |
| BioArctic AB (publ) | 252.64 Million SEK | 141.943% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 72.433% |
| Camurus AB (publ) | 532.35 Million SEK | 119.905% |
| Cantargia AB (publ) | -290.01 Million SEK | 63.462% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -426.168% |
| Genovis AB (publ.) | 54.22 Million SEK | 295.421% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 7.915% |
| Mendus AB (publ) | -100.65 Million SEK | -5.281% |
| Kancera AB (publ) | -65.04 Million SEK | -62.918% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -2923.252% |
| LIDDS AB (publ) | -40.67 Million SEK | -160.523% |
| Lipum AB (publ) | -37.25 Million SEK | -184.439% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -756.56% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 688.4% |
| NextCell Pharma AB | -43.17 Million SEK | -145.448% |
| OncoZenge AB (publ) | -15.9 Million SEK | -566.363% |
| Saniona AB (publ) | -81.06 Million SEK | -30.716% |
| Simris Alg AB (publ) | -36.63 Million SEK | -189.245% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 67.041% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 65.865% |
| Xintela AB (publ) | -57.23 Million SEK | -85.131% |
| Ziccum AB (publ) | -21.56 Million SEK | -391.489% |
| AcouSort AB (publ) | -17.48 Million SEK | -505.964% |
| Active Biotech AB (publ) | -46.48 Million SEK | -127.96% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -519.813% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -546.089% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -154.216% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 41.38% |
| CombiGene AB (publ) | -36.3 Million SEK | -191.873% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 27.702% |
| Intervacc AB (publ) | -93.57 Million SEK | -13.236% |
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 57.441% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -12440.237% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -583.116% |
| Corline Biomedical AB | -1.78 Million SEK | -5826.454% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 41.38% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -91.214% |
| Aptahem AB (publ) | -10.1 Million SEK | -948.664% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 21.284% |
| Fluicell AB (publ) | -26.87 Million SEK | -294.23% |
| Biovica International AB (publ) | -126.07 Million SEK | 15.949% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -149.3% |
| Abliva AB (publ) | -96.54 Million SEK | -9.754% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 67.375% |
| 2cureX AB (publ) | -36.36 Million SEK | -191.409% |
| I-Tech AB | 24.43 Million SEK | 533.661% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 86.561% |
| Cyxone AB (publ) | -21.66 Million SEK | -389.197% |
| Biosergen AB | -27.26 Million SEK | -288.648% |
| Nanologica AB (publ) | -69.96 Million SEK | -51.459% |
| SynAct Pharma AB | -224.49 Million SEK | 52.799% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -139.87% |
| BioInvent International AB (publ) | -369.94 Million SEK | 71.356% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -342.364% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 58.19% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -1557.451% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 4.462% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -816.177% |